Genetic Screening in Patients with Craniofacial Malformations.

J Pediatr Genet

Department of Human Genetics, David Geffen School of Medicine at UCLA, Los Angeles, California; Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, California.

Published: December 2016

Craniofacial malformations include a variety of anomalies, including cleft lip with or without cleft palate, craniosynostosis, microtia, and hemifacial microsomia. All of these anomalies can be either isolated or part of a defined genetic syndrome. A clinical geneticist or genetic counselor should be a member of the craniofacial team to help determine which patients have isolated anomalies and which are likely to have a syndrome. They would then arrange for the appropriate genetic testing to confirm the diagnosis of the specific syndrome. The identification of the specific syndrome is important for the overall care of the patient (as it identifies risk for other medical problems such as congenital heart defect) that will have to be taken into account in the care of the craniofacial malformation. In addition, knowing the specific syndrome will allow the family to understand how this happened to their child and the recurrence risk for future pregnancies. With the advent of new technologies, there are now many types of genetic testing available (including, karyotype, fluorescence in situ hybridization, chromosomal microarrays, and next generation sequencing) and the medical geneticist and genetic counselor can determine which specific testing is needed for a given patient.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5123894PMC
http://dx.doi.org/10.1055/s-0036-1592423DOI Listing

Publication Analysis

Top Keywords

specific syndrome
12
craniofacial malformations
8
geneticist genetic
8
genetic counselor
8
genetic testing
8
genetic
6
syndrome
5
genetic screening
4
screening patients
4
craniofacial
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Stanford University School of Medicine, Stanford, CA, USA.

Recent advances in biomarkers, enabling the in vivo detection of pathological aggregates of alpha-synuclein (asyn), allow a shift from a clinical to a biological definition of Parkinson's disease (PD) and dementia with Lewy bodies (DLB). The newly proposed "Neuronal alpha-Synuclein Disease (NSD)" is defined by the presence of pathologic neuronal (n-asyn) species detected in vivo (S), irrespective of any specific clinical syndrome. Additional biological anchors include dopaminergic neuronal dysfunction (D).

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

University of California, Irvine, Irvine, CA, USA.

Background: Recruitment challenges in people with and without Down syndrome (DS) can delay research progress and risk sample bias. This study identified and quantified differences in research attitudes across populations of research enrollment decision-makers for individuals with and without DS.

Method: We compared scores on the Research Attitudes Questionnaire (RAQ) of individuals enrolled in two recruitment registries: the UCI Consent to Contact [C2C (N = 4818)] and DS-Connect (N = 976).

View Article and Find Full Text PDF

Technology and Dementia Preconference.

Alzheimers Dement

December 2024

Cumulus Neuroscience, Dublin, Ireland.

Background: Current tools for Alzheimer's disease screening and staging used in clinical research (e.g. ACE-3, ADAS-Cog) require substantial face-to-face time with trained professionals, and may be affected by subjectivity, "white coat syndrome" and other biases.

View Article and Find Full Text PDF

Acute kidney injury following CAR-T cell therapy: a nephrologist's perspective.

Clin Kidney J

January 2025

Department of Medicine, Universidad Autonoma de Madrid and IIS-Fundacion Jimenez Diaz, Madrid, Spain.

Chimeric antigen receptor T (CAR-T) cell therapy, an emerging personalized immunotherapy for various haematologic malignancies, autoimmune diseases and other conditions, involves the modification of patients' T cells to express a chimeric antigen receptor that recognizes tumour or autoimmune cell antigens, allowing CAR-T cells to destroy cancerous and other target cells selectively. Despite remarkable clinical improvements in patients, multiple adverse effects have been associated with CAR-T cell therapy. Among the most recognized adverse effects are cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome and tumour lysis syndrome.

View Article and Find Full Text PDF

Assessment of Risk Factors Leading to Amputation Among Diabetic Septic Foot Patients in Khartoum, Sudan.

Cureus

December 2024

Trauma and Orthopaedics, Gateshead Health National Health Services (NHS) Foundation Trust, Gateshead, GBR.

Introduction  Diabetes is a rapidly growing global health concern, with the World Health Organization (WHO) estimating that 300 million adults will have diabetes by 2025. This chronic condition is associated with complications, including nephropathy, retinopathy, neuropathy, cardiovascular disease, and diabetic foot ulcers (DFUs), which can lead to amputation. Diabetic septic foot (DSF), a severe form of diabetic foot disease, is defined by the WHO as the presence of infection, ulceration, or tissue destruction in the lower limb, often accompanied by neurological abnormalities, peripheral vascular disease, and metabolic complications of diabetes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!